The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.
 
Changsong QI
No Relationships to Disclose
 
Shikai Wu
No Relationships to Disclose
 
In-Ho Kim
No Relationships to Disclose
 
Shirong Cai
No Relationships to Disclose
 
Jufeng Wang
No Relationships to Disclose
 
Seung Tae Kim
No Relationships to Disclose
 
Jaw-Yuan Wang
No Relationships to Disclose
 
Li-Yuan Bai
Honoraria - CStone Pharmaceuticals; Ipsen; Lilly; Ono Pharmaceutical; Pfizer; SynCoreBio
Consulting or Advisory Role - Bristol-Myers Squibb; Zai Lab
Research Funding - Eisai
 
Cheng-Yao Lin
No Relationships to Disclose
 
Zhezhao Liang
Employment - LintonPharm
 
Jian Xin Wei
Employment - Anheart Therapeutics
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche
Speakers' Bureau - Hutchison Whampoa; MSD
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)